Scimeca Dario 4

What Happened Dario Scimeca, General Counsel and Secretary of Precision BioSciences (DTIL), had Restricted Stock Units (RSUs) vest on Jan 20, 2026, resulting in the conversion/receipt of 25,311 shares (1,978 + 8,425 + 14,908). Under a pre-established Rule 10b5-1 plan, 8,854 of those shares were sold on Jan 21, 2026 at $4.03 per share for proceeds of $35,682 to cover tax withholding; the RSU-to-share conversions were reported at $0.00 (no cash purchase price).

Key Details

• Transaction dates: RSU vesting/conversion reported Jan 20, 2026; open-market sale on Jan 21, 2026. Form 4 filed Jan 22, 2026 (appears timely).
• Prices and values: Shares converted reported at $0.00; 8,854 shares sold at $4.03 each, netting $35,682.
• Shares involved: 25,311 shares vested/converted in total; 8,854 sold (~35% of the vested shares) as a sell-to-cover.
• Shares owned after transaction: Not specified in this filing.
• Notable footnotes: Sale executed under a Rule 10b5-1 plan (adopted Sept 29, 2025) and described as a sell-to-cover to satisfy tax withholding; RSUs originated from grants on Jan 20, 2023; Apr 18, 2024; and Aug 22, 2024 with multi-year vesting schedules.

Context These transactions reflect routine post-vesting activity (conversion of RSUs to common stock) and a sell-to-cover tax-withholding sale under a pre-established trading plan; such sales are common and do not by themselves indicate the insider's market view. The derivative activity reported (code M) reflects conversion/settlement of RSUs into shares rather than a cash purchase of stock.